Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glatiramer acetate 40 mg vs 20 mg once-daily in relapsing-remitting multiple sclerosis
2006-002037-20Phase 3Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- May 2006
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of glatiramer acetate in multiple sclerosis (MS) (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Total number of confirmed relapses. Started May 2006; status: terminated.
02
Drugs
glatiramer acetate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2006-002037-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002037-20.